Diotheris SAS | DECOLONIZE | 1b | Other | Precise Pathogen ID Priority Pathogen * Decolonization of S.aureus MR | New Class New Target New MoA | Discovery |
Diotheris SAS | PREVENT | 1b | Other | Precise Pathogen ID Priority Pathogen * Prevent infection by S.aureus MR | New Class New Target New MoA | Pre-clinical |
Aptorum Group Ltd | ALS-3 | 3d | Other | Gram + Priority Pathogen * Reviving existing antibiotics to overcome drug Resistance | New Class New Target New MoA | Lead opt |
Aptorum Group Ltd | ALS-2 | 4a | Other | Gram + Priority Pathogen * Treatment of bacterial infections casued by Gram Positive Bacteria including Staphylococcus aureus (MRSA) | New Class New Target New MoA | Lead opt |
Aptorum Group Ltd | ALS-1 | 3a | Other | Precise Pathogen ID Priority Pathogen * Treatment of viral infections casued by influenza virus A | New Class New Target New MoA | Lead opt |
Aptorum Group Ltd | ALS-4 | 3c | Other | Precise Pathogen ID Priority Pathogen * Treatment of bacterial infections casued by Staphylococcus aureus infections including MRSA | New Class New Target New MoA | Pre-clinical |
Debiopharm International | 1454/S | 3a | NME | Gram - Priority Pathogen * Hospital-acquired or Ventilator-acquired bacterial pneumoniae (HABP/VABP) | New Class New Target New MoA | Lead opt |
OLGRAM | Ol20-01 | | Protein/Peptide | Broad Gram +/- Priority Pathogen * Infectious relapses | New Class New MoA | Pre-clinical |
Selmod GmbH | slm 500 | 3a | NME | Broad Gram +/- Priority Pathogen * | New Class New Target New MoA | Pre-clinical |
Selmod GmbH | slm 400 | 3a | NME | Gram - Priority Pathogen * | New Class New Target New MoA | Discovery |
Selmod GmbH | slm 300 | 3a | NME | Gram - Priority Pathogen * | New Class New Target New MoA | Discovery |
Selmod GmbH | slm 200 | 3a | NME | Precise Pathogen ID Priority Pathogen * C.C. albicans, flucanozole-resistant; Drug-resistant Aspergillus; Drug-resistant C. auris | New MoA | Lead opt |
Selmod GmbH | slm 100 | 3a | NME | Precise Pathogen ID Priority Pathogen * C. albicans, flucanozole-resistant; Drug-resistant Aspergillus; Drug-resistant C. auris | New Class New Target New MoA | Lead opt |
PhagoMed Biopharma GmbH | PM-477 | 3a | Protein/Peptide | Precise Pathogen ID Endolysin specific to bacteria of the genus Gardnerella to treat Bacterial Vaginosis | New Target | Lead opt |
Nabriva Therapeutics GmbH | BC-2126 | 3a | NME | Gram - Priority Pathogen * Respiratory tract infections caused by P. aeruginosa, A. baumannii and Burkholderia cepacia complex | New Class New MoA | Pre-clinical |
Nabriva Therapeutics GmbH | BC-7013 | 3a | NME | Broad Gram +/- Priority Pathogen * Topical treatment of skin and skin structure infections | | Phase I |
Destiny Pharma plc | XF-73 | 3a | NME | Broad Gram +/- Priority Pathogen * Dermal wound infections | New Class New Target New MoA | Phase I |
Combioxin SA | CX195 | 4a | Other | Gram - Priority Pathogen * Severe Gram- resistant infections | New Class New Target New MoA | Lead opt |
Alaxia | ALX-009 | 3a | Other | Broad Gram +/- Priority Pathogen * Bronchiectasis | New Class New Target New MoA | Phase I |
AiCuris Anti-infective Cures GmbH | NPI Scaffolds | 3a | NME | Gram - Priority Pathogen * Undisclosed | New Class New Target New MoA | Discovery |
AiCuris Anti-infective Cures GmbH | Macrocyles | 3a | NME | Gram - Priority Pathogen * Undisclosed | New Class New Target New MoA | Discovery |
Juvabis AG | JUV-385 | 3a | NME | Broad Gram +/- Priority Pathogen * Systemic Gram-negative, Gram-positive and mycobacterial infections by multidrug-resistant pathogens, including cUTI, BSI, cIAI, HAP/VAP. | | Lead opt |
Juvabis AG | EBL-1003 | 3a | NME | Broad Gram +/- Priority Pathogen * Systemic Gram-negative infections by multidrug-resistant pathogens, including cUTI, BSI, cIAI, HAP/VAP | | Phase I |
MaaT Pharma | MaaT033 | 3c | Other | Broad Gram +/- Priority Pathogen * Acute Myeloid Leukemia | New Class New Target New MoA | Phase I |
MaaT Pharma | MaaT013 | 3c | Other | Broad Gram +/- Priority Pathogen * GvHD | New Class New Target New MoA | Phase II |
MaaT Pharma | MaaT012 | 5b | Other | Broad Gram +/- Acute Myeloid Leukemia | New Class New Target New MoA | Phase II |
Basilea Pharmaceutica International Ltd. | undisclosed | 3a | NME | Gram - Priority Pathogen * Serious infections in hospitalized patients | New Class | Lead opt |
Basilea Pharmaceutica International Ltd. | Non beta-lactam PBP inhibitor | 3a | NME | Gram - Priority Pathogen * Serious infections in hospitalized patients | New Class | Lead opt |
Pherecydes Pharma | PP1151 | 3a | Phage | Precise Pathogen ID Priority Pathogen * MDR infections to Escherichia coli | New Class New MoA | Pre-clinical |
Pherecydes Pharma | PP1002 | 3a | Phage | Precise Pathogen ID Priority Pathogen * MDR infections to Escherichia coli | New Class New MoA | Pre-clinical |
Pherecydes Pharma | PP970 | 3a | Phage | Precise Pathogen ID Priority Pathogen * MDR infections to Escherichia coli | New Class New MoA | Pre-clinical |
Pherecydes Pharma | PP954 | 3a | Phage | Precise Pathogen ID Priority Pathogen * MDR infections to Escherichia coli | New Class New MoA | Pre-clinical |
Pherecydes Pharma | PP814 | 3a | Phage | Precise Pathogen ID Priority Pathogen * MDR infections to Escherichia coli | New Class New MoA | Pre-clinical |
Pherecydes Pharma | PP700 | 3a | Phage | Precise Pathogen ID Priority Pathogen * MDR infections to Escherichia coli | New Class New MoA | Pre-clinical |
Assuré Medical Limited | Sol-UTI | 1b | Other | Gram - Priority Pathogen * Recurrent Urinary Tract Infection (rUTI) | New Target New MoA | Pre-clinical |
BioVersys AG | BV100 | 3a | NME | Gram - Priority Pathogen * A. baumannii (HAP,VAP, BSI) | New MoA | Pre-clinical |
Madam Therapeutics BV | P10 | 3a | Protein/Peptide | Broad Gram +/- Priority Pathogen * Veterinary Diseases (companion animals and lifestock) | New Class New Target New MoA | Pre-clinical |
Destiny Pharma plc | DPD-207 | 3a | NME | Gram + Priority Pathogen * MDR bacterial eye infections | New Class New Target New MoA | Pre-clinical |
Alphanosos | W9P154 | 3e | Other | Precise Pathogen ID Priority Pathogen * Tuberculosis, Buruli Ulcer | New Class New Target New MoA | Lead opt |
ABAC therapeutics | ABAC-40,244 | 3a | NME | Precise Pathogen ID Priority Pathogen * Infections by MDR/XDR Staph aureus | New Class New Target New MoA | Lead opt |
ABAC therapeutics | ABAC-40105 | 3a | NME | Gram - Priority Pathogen * Infections by MDR/XDR A baumannii, including ColistinR and CarbapenemR | New Class New Target New MoA | Lead opt |
ANTABIO S.A.S | ANT3310 | 3d | NME | Gram - Priority Pathogen * Hospital-acquired infections caused by carbapenem-resistant Enterobacteriaceae (CRE) and Acinetobacter [cUTI, cIAI, Nosocomial Pneumonia] | New MoA | Pre-clinical |
VibioSphen | Sativa | 3b | NME | Pulmonary infection, UTI | | Pre-clinical |
VAXDYN | VXD-002 | 1a | Vaccine | Precise Pathogen ID Priority Pathogen * Hospital/community acquired untreatable or difficult-to-treat infections, caused by Pseudomonas aeruginosa, Klebsiella pneumoniae, and Acinetobacter baumannii | New Class New Target New MoA | Lead opt |
VAXDYN | VXD-003 | 3c | Antibody | Precise Pathogen ID Priority Pathogen * Hospital/community acquired untreatable or difficult-to-treat infections, caused by Acinetobacter baumannii | New Class New Target New MoA | Lead opt |
VAXDYN | VXD-001 | 1a | Vaccine | Precise Pathogen ID Priority Pathogen * Hospital/community acquired untreatable or difficult-to-treat infections, caused by Acinetobacter baumannii | New Class New Target New MoA | Pre-clinical |
Summit Therapeutics plc | SMT026571 | 3a | NME | Gram - Priority Pathogen * Gonorrhoea infection | New Class New Target New MoA | Pre-clinical |
Summit Therapeutics plc | Ridinilazole | 3a | NME | Gram + Priority Pathogen * Clostridium difficile infection | New Class New Target New MoA | Phase III |
SetLance srl | SET-M33 | 3a | Protein/Peptide | Broad Gram +/- Priority Pathogen * Sepsis, pneumonia and skin infections | | Pre-clinical |
QureTech Bio AB | TIB | 3a | NME | Precise Pathogen ID Trachoma, Chlamydia eye infection | New Class New Target New MoA | Lead opt |
QureTech Bio AB | GmP | 3d | NME | Gram + Priority Pathogen * VRE and MRSA | New Class New Target New MoA | Lead opt |
QureTech Bio AB | CIB | 3a | NME | Precise Pathogen ID Priority Pathogen * Genital Chlamydia infection | New Class New Target New MoA | Lead opt |
QureTech Bio AB | MTI | 3d | NME | Precise Pathogen ID Priority Pathogen * MDR Tuberculosis | New Class New Target New MoA | Pre-clinical |
Polyphor Ltd | Murepavadin (inhaled) | 3a | Protein/Peptide | Gram - Priority Pathogen * Cystic Fibrosis; Bronchiectasis | New Class New Target New MoA | Pre-clinical |
Polyphor Ltd | OMPTA | 3a | Protein/Peptide | Gram - Priority Pathogen * HAP, VAP, UTI, IAI, other | New Class New Target New MoA | Pre-clinical |
Phico Therapeutics Ltd | SASPject™ PT4 | 3a | Other | Precise Pathogen ID Priority Pathogen * Serious Klebsiella Pneumoniae infections where treatment options are limited | New Target New MoA | Pre-clinical |
Phico Therapeutics Ltd | SASPject™ PT5 | 3a | Other | Precise Pathogen ID Priority Pathogen * Serious E.coli infections where treatment options are limited | New Target New MoA | Pre-clinical |
Phico Therapeutics Ltd | SASPject™ PT3.8 | 3a | Other | Precise Pathogen ID Priority Pathogen * Serious Pseudomonas Aeruginosa infections where treatment options are limited | New Target New MoA | Pre-clinical |
Pherecydes Pharma | PN1777 | 3a | Phage | Precise Pathogen ID Priority Pathogen * MDR infections to Pseudomonas aeruginosa | New Class New MoA | Pre-clinical |
Pherecydes Pharma | PN1792 | 3a | Phage | Precise Pathogen ID Priority Pathogen * MDR infections to Pseudomonas aeruginosa | New Class New MoA | Pre-clinical |
Pherecydes Pharma | PN1797 | 3a | Phage | Precise Pathogen ID Priority Pathogen * MDR infections to Pseudomonas aeruginosa | New Class New MoA | Pre-clinical |
Pherecydes Pharma | PN1493 | 3a | Phage | Precise Pathogen ID Priority Pathogen * MDR infections to Staphylococcus aureus | New Class New MoA | Pre-clinical |
Pherecydes Pharma | PN1815 | 3a | Phage | Precise Pathogen ID Priority Pathogen * MDR infections to Staphylococcus aureus | New Class New MoA | Pre-clinical |
Pherecydes Pharma | PN1957 | 3a | Phage | Precise Pathogen ID Priority Pathogen * MDR infections to Staphylococcus aureus | New Class New MoA | Pre-clinical |
Pherecydes Pharma | PN1450 | 3a | Phage | Precise Pathogen ID Priority Pathogen * MDR infections to Pseudomonas aeruginosa | New Class New MoA | Pre-clinical |
PhagoMed Biopharma GmbH | PhM398 | 3a | Phage | Precise Pathogen ID Priority Pathogen * Periprosthetic Joint Infections | New Class New MoA | Lead opt |
PhagoMed Biopharma GmbH | PhM754 | 3a | Phage | Precise Pathogen ID Priority Pathogen * Urinary Tract Infections | New Class New MoA | Lead opt |
Omnix Medical | OMN6 | 3a | Protein/Peptide | Gram - Priority Pathogen * A. baumannii induced Bacteremia or HABP or VABP | New Class New MoA | Lead opt |
NovaBiotics Ltd | Novamycin® | 3a | Protein/Peptide | Non Bacterial Target Priority Pathogen * Invasive Fungal Disease, mucocutaneous fungal infections | New Class New Target New MoA | Pre-clinical |
NovaBiotics Ltd | Nylexa™ | 3d | Other | Broad Gram +/- Priority Pathogen * Resistance breaker | New Class New Target New MoA | Pre-clinical |
NovaBiotics Ltd | Novarifyn® | 3a | Protein/Peptide | Broad Gram +/- Priority Pathogen * Gram negative and Gram negative reistant/MDR infections (ESKAPE), some Gram positive coverage | New Class New Target New MoA | Pre-clinical |
NovaBiotics Ltd | Luminaderm® | 1b | Protein/Peptide | Broad Gram +/- Priority Pathogen * MRSA | New Class New Target New MoA | Pre-clinical |
NovaBiotics Ltd | Lynovex® inhaled | 1a | Other | Broad Gram +/- Priority Pathogen * Cystic Fibrosis | New Class New Target New MoA | IND/CTA ready |
NovaBiotics Ltd | Novexatin® | 3a | Protein/Peptide | Non Bacterial Target Priority Pathogen * Onychomycosis | New Class New Target New MoA | Phase II |
NovaBiotics Ltd | Lynovex® oral | 3b | Other | Broad Gram +/- Priority Pathogen * Cystic Fibrosis | New Class New Target New MoA | Phase II |
Nosopharm | NOSO-A4 | 3a | NME | Broad Gram +/- Priority Pathogen * P. aeruginosa infections | New Class New Target New MoA | Discovery |
Nosopharm | NOSO-502 | 3a | NME | Gram - Priority Pathogen * MDR Enterobacteriaceae infections | New Class New Target New MoA | Pre-clinical |
Northern Antibiotics Oy (Ltd) | NAB815 | 3a | Protein/Peptide | Gram - Priority Pathogen * cUTI caused by MDR Gram-negatives | | Pre-clinical |
Northern Antibiotics Oy (Ltd) | NAB739 | 3a | Protein/Peptide | Gram - Priority Pathogen * cUTI caused by MDR Gram-negatives | | Pre-clinical |
Nabriva Therapeutics GmbH | Lefamulin | 3a | NME | Broad Gram +/- Priority Pathogen * ABSSSI | New Class New Target New MoA | Phase II |
Nabriva Therapeutics GmbH | Lefamulin | 3a | NME | Broad Gram +/- Priority Pathogen * STIs, HABP/VABP, Osteomyelitis, Prosthetic Joint Infections | New Class New Target New MoA | Pre-clinical |
Nabriva Therapeutics GmbH | Lefamulin | 3a | NME | Broad Gram +/- Priority Pathogen * Pediatric Indications | New Class New Target New MoA | Phase I |
Nabriva Therapeutics GmbH | Lefamulin | 3a | NME | Broad Gram +/- Priority Pathogen * CABP (community-acquired bacterial pneumonia) | New Class New Target New MoA | Phase III |
Mutabilis SAS | 2G-DABOCIN | 3a | NME | Gram - Priority Pathogen * IV treatment against Enterobacterales & non-fermenters | New Class | Lead opt |
Mutabilis SAS | EBL-1463 | 3a | NME | Gram - Priority Pathogen * IV treatment against Enterobacterales | New Class | Pre-clinical |
Madam Therapeutics BV | SAAP148 | 3a | Protein/Peptide | Broad Gram +/- Priority Pathogen * Diabetic foot ulcers, burns and MRSA carriership | New Class New Target New MoA | Pre-clinical |
MaaT Pharma | MaaT011 | 5a | Other | Broad Gram +/- Acute Myeloid Leukemia | New Class New Target New MoA | Phase II |
MaaT Pharma | MaaT031 | 1b | Other | Broad Gram +/- Bone and Joint Infectious | New Class New Target New MoA | Phase I |
IMMUNETHEP, SA | Unimab | 3c | Antibody | Broad Gram +/- Priority Pathogen * Intensive Care Units / Hospital Acquired infections | New Class New Target New MoA | Pre-clinical |
IMMUNETHEP, SA | cPNV | 1a | Vaccine | Broad Gram +/- Priority Pathogen * Preventive | New Class New Target | Pre-clinical |
Hypharm GmbH | HY-133 | 1b | Phage | Gram + Priority Pathogen * Nasal colonization with MRSA | New Class New Target New MoA | Pre-clinical |
Helperby Therapeutics Ltd | HY-001 | 3d | Other | Gram - Priority Pathogen * Urinary Tract Infections | New Class New Target New MoA | Phase II |
Helperby Therapeutics Ltd | HY-002 | 3d | Other | Gram - Priority Pathogen * Intra-Abdominal Infections | New Class New Target New MoA | Phase I |
Helperby Therapeutics Ltd | HY-004 | 1b | Other | Gram + Priority Pathogen * Nasal MRSA decolonisation | New Class New Target New MoA | Phase II |
Helperby Therapeutics Ltd | HY-005 | 3d | Other | Gram + Priority Pathogen * Skin & Soft Tissue MRSA | New Class New Target New MoA | Phase II |
Eligo Bioscience | EB004 | 1b | Other | Precise Pathogen ID Priority Pathogen * Multi-drug resistant Enterobacteriaceae | New Class New MoA | Pre-clinical |
Destiny Pharma plc | XF-73 | 3d | NME | Broad Gram +/- Priority Pathogen * Hospital pneumonia/ventilator-associated pneumonia (VAP) | New Class New Target New MoA | Pre-clinical |
Destiny Pharma plc | XF-70 | 1b | NME | Broad Gram +/- Priority Pathogen * Bacterial biofilm-infections | New Class New Target New MoA | Pre-clinical |
Destiny Pharma plc | XF-73 | 1b | NME | Broad Gram +/- Priority Pathogen * Prevention of post-surgical infection | New Class New Target New MoA | Phase II |
DEINOVE | DNV3837 | 3a | NME | Broad Gram +/- Priority Pathogen * C.difficile gastrointestinal infections | New Class New MoA | Phase II |
Debiopharm International | Debio 1453 | 3a | NME | Gram - Priority Pathogen * N. gonorrhoeae infections | New Class New Target New MoA | Lead opt |
Debiopharm International | Afabicin (Debio 1450) | 3a | NME | Precise Pathogen ID Priority Pathogen * ABSSSI, Bone & Joint Infections (BJIs) | New Class New Target New MoA | Phase II |
Combioxin SA | CAL02 | 4a | Other | Broad Gram +/- Priority Pathogen * Severe infections | New Class New Target New MoA | Phase II |
Centauri Therapeutics Ltd | ABX01 | 3c | Other | Gram - Priority Pathogen * Broad spectrum Gram negative, including clinically-relevant strains of Enterobacteriaceae, P. aeruginosa, and A. baumannii | New Class New Target New MoA | Pre-clinical |
Centauri Therapeutics Ltd | ABX02 | 3c | Other | Precise Pathogen ID Priority Pathogen * Pseudomonas Aeruginosa specific Inhibitor | New Class New Target New MoA | Pre-clinical |
BioVersys AG | BV200 | 4a | NME | Gram + Priority Pathogen * Anti-toxin for Staphylococcus aureus | New Class New Target New MoA | Lead opt |
BioVersys AG | BV400 | 3b | NME | Gram - Priority Pathogen * Anti Virulence in Gram negative bacteria, Enterobacteriaceae and A. baumannii | New Class New Target New MoA | Lead opt |
BioVersys AG | BVL-GSK098 | 3d | NME | Precise Pathogen ID Priority Pathogen * Adjuvant reversing resistance and potentiating Ethionamide activity in Tuberculosis | New Class New Target New MoA | Pre-clinical |
BioFilm Pharma | BFP002 | 3e | NME | Broad Gram +/- Priority Pathogen * Staphylococcus aureus, Pseudomonas aeruginosa Systemic – Cystic Fibrosis | New Target New MoA | Lead opt |
BioFilm Pharma | BFP101 | 3e | NME | Gram + Priority Pathogen * Staphylococcus aureus Local - Diabetic Foot Ulcer, Joint & Bone Infections | New Target New MoA | Lead opt |
BioFilm Pharma | BFP102 | 3e | NME | Broad Gram +/- Priority Pathogen * Staphylococcus aureus, Pseudomonas aeruginosa Systemic – Cystic Fibrosis | New Class New Target New MoA | Lead opt |
BioFilm Pharma | BFP001 | 3e | NME | Gram + Priority Pathogen * Staphylococcus aureus Local - Diabetic Foot Ulcer, Joint & Bone Infections | New Class New Target New MoA | Lead opt |
Basilea Pharmaceutica International Ltd. | Ceftobiprole | 3a | NME | Broad Gram +/- Priority Pathogen * Acute bacterial skin and skin structure infections, Staphylococcus aureus bacteremia | | Phase III |
Basilea Pharmaceutica International Ltd. | Ceftobiprole | 3a | NME | Broad Gram +/- Priority Pathogen * Community- and hospital-acquired pneumonia (excluding ventilator-associated pneumonia) | | Marketed |
ANTABIO S.A.S | ANT_Pei | 3c | NME | Precise Pathogen ID Priority Pathogen * Pseudomonas infections in Cystic Fibrosis patients | New Class New Target New MoA | Pre-clinical |
ANTABIO S.A.S | ANT2681 | 3d | NME | Gram - Priority Pathogen * Hospital-acquired infections caused by carbapenem-resistant Enterobacteriaceae (CRE) [cUTI, cIAI, Nosocomial Pneumonia] | New Class New Target New MoA | Pre-clinical |
Alphanosos | W16P0576 | 3e | Other | Broad Gram +/- Priority Pathogen * A. baumannii, P. aeruginosa, MRSA,N. gonorrhoeae, M. tuberculosis - Infectious skin conditions (eczema, acne, sporiasis, ...), difficult wounds | New Class New Target New MoA | Pre-clinical |
ALLECRA THERAPEUTICS | Cefepime / Enmetazobactam | 3d | NME | Broad Gram +/- Priority Pathogen * cUTI, cIAI, HAP | | Phase II |
Alaxia | ALX-009 | 3a | Other | Broad Gram +/- Priority Pathogen * Cystic Fibrosis | New Class New Target New MoA | Phase I |
Akthelia | HO53/HO56 ADP | 3c | NME | Broad Gram +/- Priority Pathogen * Multidrug resistant lung infections including nosocomial infections (K. pneumoniae) | New Class New Target New MoA | Lead opt |
AiCuris Anti-infective Cures GmbH | Artilysins | 3a | Protein/Peptide | Gram - Priority Pathogen * Undisclosed | New Class New MoA | Lead opt |
AGILeBiotics B.V. | ABX-395 | 3a | NME | Gram - Priority Pathogen * Hospital-treated MDR Gram-negative infections | | Lead opt |
AGILeBiotics B.V. | ABX-605 (Toframicin) | 3a | NME | Gram - Priority Pathogen * Hospital-treated MDR Gram-negative infections | | Pre-clinical |
ABAC therapeutics | ABAC-39,877 | 3a | NME | Gram - Priority Pathogen * Infections by MDR/XDR A baumannii, including ColistinR and CarbapenemR | New Class New Target New MoA | Pre-clinical |
Da Volterra | DAV121 | 4b | Other | Broad Gram +/- Priority Pathogen * Prevention of gut microbiota antibiotic-dysbiosis and emergence of resistance to β-lactam antibiotics, including carbapenems | New Class New Target New MoA | Lead opt |
Da Volterra | DAV132 | 4b | Other | Broad Gram +/- Priority Pathogen * Prevention of C.difficile infections | New Class New Target New MoA | Phase II |